Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Tsutsumi, Kosuke ^a   Sato, Norihiro ^a   Tanabe, Reiko ^a   Mizumoto, Kazuhiro ^a   Morimatsu, Katsuya ^a   Kayashima, Tadashi ^a   Fujita, Hayato ^a   Ohuchida, Kenoki ^a   Ohtsuka, Takao ^a   Takahata, Shunichi ^a   Nakamura, Masafumi ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 4; FLUOROURACIL; FORMALDEHYDE; GEMCITABINE; MESSENGER RNA; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; EPITHELIUM CELL; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CLAUDIN-4; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PANCREATECTOMY; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84865035020     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1970-2     Document Type: Article

References (47)

1. MJ Eskelinen UH Haglund 1999 Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods Eur J Surg. 165 292 306 10365829 10.1080/110241599750006811 1:STN:280:DyaK1M3ptF2msw%3D%3D
2. TP Yeo RH Hruban SD Leach RE Wilentz TA Sohn SE Kern, et al. 2002 Pancreatic cancer Curr Probl Cancer 26 176 275 12399802 10.1067/mcn.2002.129579
3. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin. 59 225 249 19474385 10.3322/caac.20006
4. M Wagner C Redaelli M Lietz CA Seiler H Friess MW Buchler 2004 Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma Br J Surg. 91 586 594 15122610 10.1002/bjs.4484 1:STN:280:DC%2BD2c3it1ansA%3D%3D
5. M Carpelan-Holmstrom S Nordling E Pukkala R Sankila J Luttges G Kloppel, et al. 2005 Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut. 54 385 387 15710987 10.1136/gut.2004.047191 1:STN:280:DC%2BD2M%2FotFGqtQ%3D%3D
6. JL Cameron TS Riall J Coleman KA Belcher 2006 One thousand consecutive pancreaticoduodenectomies Ann Surg. 244 10 15 16794383 10.1097/01.sla. 0000217673.04165.ea
7. CR Ferrone DM Finkelstein SP Thayer A Muzikansky C Fernandez-delCastillo AL Warshaw 2006 Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol. 24 2897 2902 16782929 10.1200/JCO.2005.05.3934 1:CAS:528:DC%2BD28XntV2gs7o%3D
8. MW Muller H Friess J Koninger D Martin MN Wente U Hinz, et al. 2008 Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas Am J Surg. 195 221 228 18154768 10.1016/j.amjsurg. 2007.02.026
9. N Kondo Y Murakami K Uemura Y Hayashidani T Sudo Y Hashimoto, et al. 2010 Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer Ann Surg Oncol. 17 2321 2329 20336387 10.1245/s10434-010-1033-0
10. A Blackford OK Serrano CL Wolfgang G Parmigiani S Jones X Zhang, et al. 2009 SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer Clin Cancer Res. 15 4674 4679 19584151 10.1158/1078-0432.CCR-09-0227 1:CAS:528:DC%2BD1MXosV2ltLg%3D
11. FA Sinicrope DB Evans SD Leach KR Cleary CJ Fenoglio JJ Lee, et al. 1996 bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome Clin Cancer Res. 2 2015 2022 9816161 1:CAS:528: DyaK2sXitlKqsA%3D%3D
12. Y Nio M Dong C Iguchi K Yamasawa T Toga M Itakura, et al. 2001 Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy J Surg Oncol. 76 188 196 11276023 10.1002/jso.1033 1:CAS:528:DC%2BD3MXislyrsbg%3D
13. H Yamamoto F Itoh S Iku Y Adachi H Fukushima S Sasaki, et al. 2001 Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression J Clin Oncol. 19 1118 1127 11181677 1:CAS:528:DC%2BD3MXhvFertr0%3D
14. LE Jones MJ Humphreys F Campbell JP Neoptolemos MT Boyd 2004 Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival Clin Cancer Res. 10 2832 2845 15102692 10.1158/1078-0432.CCR-1157-03 1:CAS:528:DC%2BD2cXjt1Clur8%3D
15. B Gerdes A Ramaswamy A Ziegler SA Lang M Kersting R Baumann, et al. 2002 p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb Ann Surg. 235 51 59 11753042 10.1097/00000658-200201000-00007
16. YE Joo JS Rew CS Park SJ Kim 2002 Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma Pancreatology. 2 129 137 12123093 10.1159/000055903 1:CAS:528:DC%2BD38XjtlSjtL4%3D
17. M Niedergethmann R Hildenbrand B Wostbrock M Hartel JW Sturm A Richter, et al. 2002 High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas Pancreas. 25 122 129 12142733 10.1097/00006676-200208000-00002
18. K Kuwahara T Sasaki Y Kuwada M Murakami S Yamasaki K Chayama 2003 Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival Pancreas. 26 344 349 12717266 10.1097/00006676-200305000-00006 1:CAS:528:DC%2BD2cXks1Ortg%3D%3D
19. G Garcea CP Neal CJ Pattenden WP Steward DP Berry 2005 Molecular prognostic markers in pancreatic cancer: a systematic review Eur J Cancer. 41 2213 2236 16146690 10.1016/j.ejca.2005.04.044 1:CAS:528:DC%2BD2MXhtVynurfO
20. E Giovannetti M Del Tacca V Mey N Funel S Nannizzi S Ricci, et al. 2006 Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res. 66 3928 3935 16585222 10.1158/0008-5472.CAN-05-4203 1:CAS:528:DC%2BD28XjtVOqs7k%3D
21. N Ikenaga K Ohuchida K Mizumoto J Yu H Fujita K Nakata, et al. 2009 S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma J Gastrointest Surg. 13 1852 1858 19653048 10.1007/s11605-009-0978-4
22. CD Hough CA Sherman-Baust ES Pizer FJ Montz DD Im NB Rosenshein, et al. 2000 Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer Cancer Res. 60 6281 6287 11103784 1:CAS:528:DC%2BD3cXos1SksbY%3D
23. H Long CD Crean WH Lee OW Cummings TG Gabig 2001 Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium Cancer Res. 61 7878 7881 11691807 1:CAS:528:DC%2BD3MXotlaku7Y%3D
24. SL Kominsky M Vali D Korz TG Gabig SA Weitzman P Argani, et al. 2004 Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4 Am J Pathol. 164 1627 1633 15111309 10.1016/S0002-9440(10)63721-2 1:CAS:528:DC%2BD2cXns1Gqurs%3D
25. B Ryu J Jones MA Hollingsworth RH Hruban SE Kern 2001 Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers Cancer Res. 61 1833 1838 11280733 1:CAS:528: DC%2BD3MXit1OhurY%3D
26. CA Iacobuzio-Donahue A Maitra M Olsen AW Lowe NT van Heek C Rosty, et al. 2003 Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays Am J Pathol. 162 1151 1162 12651607 10.1016/S0002-9440(10)63911-9 1:CAS:528:DC%2BD3sXjtVemtL0%3D
27. KJ Hewitt R Agarwal PJ Morin 2006 The claudin gene family: expression in normal and neoplastic tissues BMC Cancer. 6 186 16836752 10.1186/1471-2407-6-186
28. P Michl C Barth M Buchholz MM Lerch M Rolke KH Holzmann, et al. 2003 Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer Cancer Res. 63 6265 6271 14559813 1:CAS:528: DC%2BD3sXotV2jurc%3D
29. K Ohuchida K Mizumoto M Murakami LW Qian N Sato E Nagai, et al. 2004 Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions Cancer Res. 64 3215 3222 15126362 10.1158/0008-5472.CAN-03-2464 1:CAS:528:DC%2BD2cXjs1ehtL4%3D
30. MG Bachem E Schneider H Gross H Weidenbach RM Schmid A Menke, et al. 1998 Identification, culture, and characterization of pancreatic stellate cells in rats and humans Gastroenterology. 115 421 432 9679048 10.1016/S0016-5085(98) 70209-4 1:STN:280:DyaK1czktl2qtA%3D%3D
31. Hruban RH, Boffetta P, Hiraoka N, et al. Ductal adenocarcinoma of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010. p. 281-91.
32. Sobin L, Wittekind C. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. In: TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002.
33. K Ohuchida K Mizumoto Y Ogura N Ishikawa E Nagai K Yamaguchi, et al. 2005 Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer Clin Cancer Res. 11 2285 2292 15788678 10.1158/1078-0432.CCR-04-1581 1:CAS:528:DC%2BD2MXisFaju7s%3D
34. HN Abrahamsen T Steiniche E Nexo SJ Hamilton-Dutoit BS Sorensen 2003 Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients J Mol Diagn. 5 34 41 12552078 10.1016/S1525- 1578(10)60449-7 1:CAS:528:DC%2BD3sXhs1Wnsbk%3D
35. J Antonov DR Goldstein A Oberli A Baltzer M Pirotta A Fleischmann, et al. 2005 Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization Lab Invest. 85 1040 1050 15951835 10.1038/labinvest.3700303 1:CAS:528:DC%2BD2MXhtVGmtLzP
36. H Jung KH Jun JH Jung HM Chin WB Park 2011 The expression of Claudin-1, Claudin-2, Claudin-3, and Claudin-4 in gastric cancer tissue J Surg Res. 167 e185 e191 20462599 10.1016/j.jss.2010.02.010 1:CAS:528:DC%2BC3MXkvFaqsbg%3D
37. AC Hoffmann R Mori D Vallbohmer J Brabender E Klein U Drebber, et al. 2008 High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF Neoplasia. 10 674 679 18592007
38. T Kinugasa T Sakaguchi X Gu HC Reinecker 2000 Claudins regulate the intestinal barrier in response to immune mediators Gastroenterology. 118 1001 1011 10833473 10.1016/S0016-5085(00)70351-9 1:CAS:528:DC%2BD3cXktlaitbY%3D
39. TA Martin RE Mansel WG Jiang 2002 Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells J Cell Physiol. 192 268 275 12124772 10.1002/jcp.10133 1:CAS:528:DC%2BD38XlvFertbw%3D
40. J Ren J Hamada N Takeichi S Fujikawa H Kobayashi 1990 Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma Cancer Res. 50 358 362 2295075 1:STN:280:DyaK3c7gs1Gjsw%3D%3D
41. SA Rajasekaran LG Palmer K Quan JF Harper WJ Ball Jr NH Bander, et al. 2001 Na, K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility Mol Biol Cell. 12 279 295 11179415 1:CAS:528:DC%2BD3MXhtlGjtL0%3D
42. C Hsueh YS Chang NM Tseng CT Liao S Hsueh JH Chang, et al. 2010 Expression pattern and prognostic significance of claudins 1, 4, and 7 in nasopharyngeal carcinoma Hum Pathol. 41 944 950 20334898 10.1016/j.humpath.2010. 01.005 1:CAS:528:DC%2BC3cXnsValurg%3D
43. S Ohtani M Terashima J Satoh N Soeta Z Saze S Kashimura, et al. 2009 Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival Gastric Cancer. 12 43 51 19390931 10.1007/s10120-008-0497-0 1:CAS:528: DC%2BD1MXosleisLk%3D
44. P Michl M Buchholz M Rolke S Kunsch M Löhr B McClane, et al. 2001 Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin Gastroenterology. 121 678 684 11522752 10.1053/gast.2001.27124 1:CAS:528:DC%2BD3MXntVKnsbc%3D
45. M Suzuki M Kato-Nakano S Kawamoto A Furuya Y Abe H Misaka, et al. 2009 Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers Cancer Sci. 100 1623 1630 19555390 10.1111/j.1349-7006.2009.01239.x 1:CAS:528:DC%2BD1MXhtFOhurvF
46. H Kakutani M Kondoh R Saeki M Fujii Y Watanabe H Mizuguchi, et al. 2010 Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens enterotoxin Eur J Pharm Biopharm. 75 213 217 20226859 10.1016/j.ejpb.2010.03.003 1:CAS:528:DC%2BC3cXmsVejsrw%3D
47. CA Foss JJ Fox G Feldmann A Maitra C Iacobuzio-Donohue SE Kern, et al. 2007 Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer Mol Imaging. 6 131 139 17445507